Jun 4 — 8, 2021

2021 ASCO Conference

 Oral presentation of abstract to showcase exciting results stemming from novel
non-engineered therapeutic cells made from CLL patients

On-demand session at ASCO 2021 starts 9:00 am Friday 4 June 2021

Woburn, MA – May 24, 2021—Alloplex Biotherapeutics is pleased to announce its participation at the 2021 ASCO Conference to be held June 4 – 8, 2021, with the acceptance of its abstract for oral presentation.

  • Abstract Number for Publication: 7517
  • Abstract Title: Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells.
  • Session Title: Poster Discussion Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  • On-Demand Session Release Date and Time: 6/4/2021, 9:00 AM-10:00 AM

Alloplex CEO Frank Borriello stated, “I am thrilled that we will get a chance to showcase the exciting results stemming from our collaboration with Dr. Jennifer Brown of the Dana Farber Cancer Institute documenting the nature of SUPLEXA therapeutic cells made from CLL patients”.

About SUPLEXA Therapeutic Cells

SUPLEXA Therapeutic Cells are an autologous cellular therapy intended to treat cancer. They are manufactured from peripheral white blood cells (PBMC). Following a short ex vivo activation procedure, the PBMC are differentiated into a mixed population of cells comprised of NK, NK-T and T cells. SUPLEXA therapeutic cells are capable of recognizing and lysing a broad range of tumor cells without harming normal cells.

About Alloplex Biotherapeutics, Inc and Pty Ltd.

Alloplex Biotherapeutics is a privately held, Boston-based, preclinical stage, cellular therapeutics company founded in 2016 by its CEO Dr. Frank Borriello, MD, PhD.

Media Relations and Investor Relations contact

office@alloplexbio.com